Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleWorkshops and Special Sessions

PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials

Ana-Maria Orbai, Richard Holland, Ying Ying Leung, William Tillett, Niti Goel, Robin Christensen, Neil McHugh, Laure Gossec, Maarten de Wit, Pil Højgaard, Laura C. Coates, Philip J. Mease, Julie Birt, Lara Fallon, Oliver FitzGerald, Alexis Ogdie, Beverly Shea, Vibeke Strand, Kristina Callis Duffin, Peter Tugwell, Dorcas Beaton and Dafna D. Gladman
The Journal of Rheumatology August 2019, 46 (8) 990-995; DOI: https://doi.org/10.3899/jrheum.181077
Ana-Maria Orbai
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore; Department of Medicine, Duke University School of Medicine, Durham, North Carolina; Kezar Life Sciences, South San Francisco; Division of Immunology, Stanford University, Palo Alto, California; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Global Patient Outcomes and Real World Evidence, Eli Lilly and Co., Indianapolis, Indiana; University of Pennsylvania, Philadelphia, Pennsylvania; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; Royal Prince Alfred Hospital Medical Centre, Sydney, Australia; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Royal National Hospital for Rheumatic Diseases, Bath; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Musculoskeletal Statistics Unit: The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen; Department of Rheumatology, Odense University Hospital, Odense, Denmark; Sorbonne Université; Rheumatology Department, Pitié Salpêtrière Hospital, AP-HP, Paris, France; VU Medical Centre, Amsterdam, the Netherlands; Global Medical Affairs, Pfizer Inc., Montreal, Quebec; Clinical Epidemiology Program, Ottawa Hospital Research Institute; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael’s Hospital and Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute, Institute for Health Policy Management and Evaluation, University of Toronto; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada; Department of Rheumatology, St. Vincent’s University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ana-Maria Orbai
  • For correspondence: aorbai1@jhmi.edu
Richard Holland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ying Ying Leung
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Tillett
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Niti Goel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robin Christensen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neil McHugh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laure Gossec
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maarten de Wit
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Maarten de Wit
Pil Højgaard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura C. Coates
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip J. Mease
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie Birt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lara Fallon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver FitzGerald
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexis Ogdie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alexis Ogdie
Beverly Shea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vibeke Strand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristina Callis Duffin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Tugwell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dorcas Beaton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dafna D. Gladman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and Outcome Measures in Rheumatology (OMERACT) psoriatic arthritis (PsA) working group is developing a Core Outcome Measurement Set for PsA clinical trials [randomized controlled trials (RCT) and longitudinal observational studies (LOS)] using the OMERACT Filter 2.1 instrument selection algorithm. Our objective was to assess the Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) for the measurement of the core domain PsA-specific health-related quality of life (HRQOL).

Methods. PsAID12 measurement property evidence gathered in a systematic literature review, and additional analyses conducted in LOS, were used to inform a consensus process. Analyses that had not been published were independently reviewed by the OMERACT technical advisory group. Data and process were presented, discussed in breakout groups, and voted on at the OMERACT conference (Terrigal, Australia, May 2018).

Results. PsAID12 fulfilled the green (good to go) OMERACT standards for domain match, feasibility, reliability, and construct/longitudinal construct validity. Discrimination and thresholds of meaning were amber (caution but good enough to go forward). The overall working group recommendation was amber/provisional endorsement of PsAID12 for measuring PsA-specific HRQOL in RCT and LOS. Of 96 participants who voted at the PsA OMERACT workshop, 87.5% (84) voted “yes” to endorse this recommendation; 14 of the 96 were patient research partners (PRP) and 93% of them (13) voted “yes”; 82 participants were not PRP and 87% of them (71) voted “yes.”

Conclusion. At OMERACT 2018, PsAID12 was the first patient-reported outcome measure provisionally endorsed as a core outcome measure for disease-specific HRQOL in PsA clinical trials. PsAID12 discrimination and improvement thresholds will be studied in future RCT.

Key Indexing Terms:
  • PSORIATIC ARTHRITIS
  • CORE SET
  • OUTCOME MEASURES
  • OMERACT
  • GRAPPA

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the Outcome Measures in Rheumatology (OMERACT) are collaborating to develop a Core Outcome Measurement Set for psoriatic arthritis (PsA). Aiming to standardize outcome measures for PsA randomized controlled trials (RCT) and longitudinal observational studies (LOS), the project is based on the GRAPPA-OMERACT updated PsA core domain set1,2 and the new OMERACT guidance on instrument selection3,4.

The OMERACT Filter 2.1 instrument selection process3,4 requires a solid definition of the target domain as documented in the core domain set. It consists of 2 major steps: (1) confirmation of content validity (domain match) and feasibility for the domain and population of interest; and (2) appraisal of construct validity and discrimination (reliability, responsiveness, thresholds of meaning). The evidence is appraised at each step and scored green (good to go), amber (caution but good enough to go forward), or red (stop, do not continue)3. For any candidate outcome measure, the OMERACT selection process can be completed only if content validity and feasibility have initially been demonstrated3,4.

Health-related quality of life (HRQOL) is a PsA core domain1, but there are few outcome measures with dedicated content validity studies to support PsA-specific HRQOL domain match5. This paper reports the first patient-reported outcome (PRO), the Psoriatic Arthritis Impact of Disease (PsAID12)6,7, appraised through the OMERACT Filter 2.1 — from core domain match with PsA-specific HRQOL to provisional endorsement as core outcome measure for PsA clinical trials (RCT and LOS).

MATERIALS AND METHODS

The GRAPPA-OMERACT project is known by the acronym “COMPACT” (Core Outcome Measures for Psoriatic Arthritis Clinical Trials)8. Figure 1 illustrates the COMPACT study design. It was applied to PsAID12, the first PRO evaluated through the OMERACT Filter 2.1. Through steps of evidence review and consensus from many people guided by Filter 2.1, a conclusion can be achieved on suitability of a candidate as core outcome measure for the desired core domain. To arrive at a complete PsA Core Outcome Measurement Set, each PsA core domain must have at least 1 corresponding outcome measure that successfully met all requirements of the OMERACT Filter 2.1 instrument selection criteria.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

The OMERACT Filter 2.1 Instrument selection algorithm is represented at the left (OMERACT handbook). The COMPACT workflow through OMERACT Filter 2.1 is represented at the right. The 4 signaling questions must be addressed in OMERACT Filter 2.1 instrument selection (items 1–4) in the left part of the figure. Following the OMERACT process, participants provide input initially into domain match and feasibility, and subsequently into the approach and results of evaluation of additional measurement properties, as well as the final voting for inclusion as core outcome measure(s). For each domain and candidate outcome measure, the OFISA Filter 2.1 is applied until a core outcome measure has been selected. The process is repeated for each core domain. Once each core domain has at least 1 corresponding core outcome measurement instrument, the PsA Core Outcome Measurement Set is complete. OMERACT: Outcome Measures in Rheumatology; COMPACT: Core Outcome Measures in Psoriatic Arthritis; OFISA: OMERACT Filter Instrument Selection Algorithm; GRAPPA: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; PsA: psoriatic arthritis; COSMIN: consensus-based standards for the assessment of health measurement instruments; LOS: longitudinal observational study; RCT: randomized controlled trial.

The working group5 completed a systematic literature review (SLR) of the evidence for measurement properties of all PRO used in PsA. PsAID12 had evidence for adequate validity and reliability for the core domain, PsA-specific HRQOL. At the time of the SLR, PsAID9, the 9-item version of PsAID12, did not have enough evidence to be considered on its own. More importantly, patient research partners (PRP) had indicated that PsAID12 met the first step of truth/domain match better than PsAID9. The SLR was updated with a focus on PsAID12 to support the ensuing consensus process9.

The PsAID12 outcome measure

The PsAID12 questionnaire6,7 was developed with PRP included in domain generation, scoring, and item formulation5. PsAID12 is available free of charge for any application in several languages. PsAID12 is composed of 12 numeric rating scales (NRS; range 0–11): (1) pain, (2) fatigue, (3) skin problems, (4) work and/or leisure activities, (5) functional capacity, (6) discomfort, (7) sleep disturbance, (8) coping, (9) anxiety, fear, and uncertainty, (10) embarrassment and/or shame, (11) social participation, and (12) depression. The total score is the sum of the weighted NRS scores. The NRS weights represent patient rankings of importance for each of the 12 items. The weighted raw score is divided by 20 to yield a final PsAID12 score (range 0–10). Higher scores represent worse life impact. The individual NRS of the PsAID12 have been evaluated in the Bath, UK, cohort10.

Domain match and feasibility

Participants were involved in 3 stages. First, GRAPPA PRP participated in a face-to-face premeeting (GRAPPA meeting July 2017). The PsA-specific HRQOL domain description was presented, followed by completion by the PRP of the OMERACT truth and feasibility questionnaires for PsAID123. Second, during the GRAPPA 2017 annual meeting COMPACT workshop, one breakout group was dedicated to PsAID12. Facilitators provided the HRQOL domain description, the PsAID12 questionnaire, and scoring method; participants then anonymously completed each item of the OMERACT domain match and feasibility questionnaires11. Third, the working group voted on domain match and feasibility.

Construct validity and discrimination

SLR PsAID12 articles were screened and selected3, and the evidence for measurement properties was extracted9 and placed in the Summary of Measurement Properties (SOMP) table (Figure 2)6,10,11,12,13,14,15,16 to record location, quality, and results of these studies. Two reviewers checked whether the study had used sufficient methods to avoid a risk of bias in its results. The COSMIN-OMERACT Good Methods Checklist was used and consensus was sought between 2 reviewers (among AMO, PH, RH, WT). Evidence from studies using good methods was extracted and compared to measurement standards and results tracked on the SOMP. Evidence from new studies was used to fill gaps and its quality was independently appraised by the OMERACT’s technical advisory group10,17. Final rating of synthesis of evidence for each measurement property was done according to OMERACT guidance, looking for consistent, good performance from studies identified as having good methods for a green rating. Amber was assigned when a noncritical limitation in the evidence was found. Amber ratings could go forward if accompanied by a research plan. These ratings were recorded on the SOMP and an overall rating for the instrument given.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

OMERACT summary of evidence for measurement properties of PsAID12. Color designates quality of evidence: green = good methods used, use this evidence; amber = some cautions but we will use this evidence. In the rating row, color designates overall evidence-based instrument rating for the core instrument set: green = at least 2 pieces of evidence with good methods and consistent findings of adequate or better performance; amber = a noncritical limitation in the evidence was found. The plus signs mean adequate or better performance of the instrument according to that study (for each measurement property studied). OMERACT: Outcome Measures in Rheumatology; PsAID: Psoriatic Arthritis Impact of Disease; TAG: Technical Advisory Group; SOMP: Summary of Measurement Properties.

Results including the SOMP were sent out to the OMERACT community in prereading materials. At OMERACT 2018, the evidence was presented in a plenary session and discussed in 8 breakout groups. After breakout group results were reported, a plenary vote was held with all OMERACT attendees.

RESULTS

SLR results and additional analyses are reported separately9. Briefly, 7 studies met inclusion criteria and were used as evidence: domain match (n = 3), feasibility (n = 2), construct validity (n = 5), test-retest reliability (n = 2), longitudinal construct validity (n = 2), and thresholds of meaning (n = 2).

Domain match and feasibility

Twelve GRAPPA PRP participated in the face-to-face meeting: 9 voted green for PsAID12 domain match with the core domain PsA-specific HRQOL, and 3 voted amber. There was a unanimous green vote for PsAID12 feasibility. At the GRAPPA 2017 annual meeting, 24 people voted majority amber for PsAID12 domain match, and majority green for feasibility11. Twenty-two working group members voted: 17 (82%) green for domain match and 20 (91%) green for feasibility; the rest of the working group votes were amber.

Construct validity and discrimination

Of 5 studies assessing construct validity, 2 had good and 3 had amber methods. PsAID12 construct validity was adequate or better based on the studies’ hypotheses. We conducted our own analysis for construct validity in an international longitudinal dataset17. Hypotheses were confirmed for correlations with similar/dissimilar constructs, and for known groups where we expected better HRQOL/PsAID12 scores in PsA subgroups with low disease activity versus high disease activity. This analysis constituted our sixth piece of evidence for construct validity with quality recorded as green.

There were 2 good quality studies for test-retest reliability with consistent adequate or better ICC in stable PsA patients (ICC 0.91–0.95). For longitudinal construct validity, there were 2 good quality studies that replicated their hypotheses regarding longitudinal magnitude of change in patients who changed treatment compared with patients who were stable over time; the 2 studies had consistent results of good longitudinal construct validity.

For discrimination in RCT, because no RCT had included PsAID12 at the time of our current work, we conducted a separate analysis in an LOS, considered bronze-level evidence based on OMERACT guidance3. In the LOS, a subset of patients had improved after medication change and could be compared to a subset of patients in the same study that had been stable with no change in therapy10. We prespecified that PsAID12 effect size would be large in the improved group and small in the stable group. The hypothesis was met and the level of evidence for discrimination in RCT recorded as amber. For green level of evidence, the analysis should have taken place in an RCT that was not available at that time, and be consistent across at least 2 studies.

Summary of PsAID12 measurement properties

The PsAID12 SOMP is presented in Figure 2. The combined rating of all the evidence and measurement properties was supportive of an amber recommendation, or provisional endorsement as core instrument along with a roadmap/research agenda to complete final endorsement. The working group is committed to derive evidence on discrimination in RCT once these datasets become available, and for thresholds of meaning in an ongoing longitudinal study.

OMERACT workshop, endorsement, and research agenda

The OMERACT PsA workshop participants, including PRP (2 per group; 2 groups only had 1) provided feedback in 8 breakout groups (Appendix 1). Suggestions were made as follows: to evaluate double-barreled NRS; to evaluate coping, and embarrassment/shame NRS for their sensitivity to change; to evaluate whether all PsAID12 NRS change in the same direction with an intervention; and importantly, to define clinically meaningful changes at the person level.

At the OMERACT PsA workshop, the working group formulated a recommendation for amber/provisional endorsement of PsAID12 to measure PsA-specific HRQOL in RCT and LOS. Of 96 participants who voted at the OMERACT PsA workshop, 87.5% (84) voted “yes,” endorsing this recommendation; 14 were PRP and 93% of them (13) voted “yes”; 82 participants were not PRP and 87% of them (71) voted “yes.” The working group set a research agenda to fully endorse PsAID12, which includes implementation in RCT to examine discrimination, and validation of PsAID12 thresholds for score interpretation.

Core Outcome Measurement Set uptake and implementation strategies were discussed and the following were recommended for PsAID12: dissemination of PsAID12 provisional endorsement as core outcome measure for PsA RCT and LOS; implementation in RCT; and SLR of clinical trial outcomes to assess whether core outcome measures are being used.

DISCUSSION

The PsAID12 is the first PRO provisionally endorsed as core outcome measure for PsA RCT and LOS, based on the OMERACT Filter 2.1 criteria. PsAID12 had a solid foundation of evidence for its measurement properties, derived from 7 studies conducted with good methods. In addition, truth/domain match received strong endorsement from the beginning from both PRP and the working group; feasibility was highly endorsed. There was evidence for consistent good measurement properties across studies, and no evidence for poor measurement properties, allowing us to conclude that it performed well as a measure of PsA-specific HRQOL in cross-sectional as well as longitudinal studies.

Our results support the OMERACT approach to sequential core set development: a disease-specific core domain set, followed by the Core Outcome Measurement Set. The rigorous process of instrument appraisal helps identify high-quality instruments to identify the core domains for patients with PsA; and combines identifying existing evidence with guiding the working group to create new evidence to fill any gaps. The involvement of multiple people with different perspectives in core set development is key to dissemination and implementation. Standardization of PsA measurement will create the evidence necessary for core domain inclusion in treatment recommendations.

HRQOL has been routinely measured in PsA RCT using the generic health survey Medical Outcomes Study Short Form-36 (SF-36)18, although its content validity for PsA has not been studied5. Content validity evidence would be necessary to pass the first critical step of the OMERACT filter3,4. Psoriatic Arthritis Quality of Life (PsAQoL) is a PsA-specific measure, but the GRAPPA-OMERACT literature review and appraisal of measurement properties showed that PsAID12 content validity was superior to PsAQoL for PsA-specific HRQOL5. Feasibility is also limiting for copyrighted measures (SF-36, PsAQoL), especially for LOS.

PsAID12 received overwhelming support at OMERACT 2018 and was provisionally endorsed as a core instrument for PsA clinical trials. The provisional designation has been chosen until PsAID12 discrimination in RCT and clinically meaningful thresholds for score interpretation can be appraised (PsAID12 research agenda). Additional candidate outcome measures are entering the OMERACT process of domain match and appraisal. The result will be a complete PsA Core Outcome Measurement Set in which each core domain will have at least 1 recommended core instrument. In the interim, clinical trial designers can use the current findings to inform their outcome measure choice for PsA-specific HRQOL in clinical trials.

Acknowledgment

Study collaborators: C.A. Lindsay, PharmD, Patient Research Partner employed by Amgen Inc., Thousand Oaks, California, USA; D. Veale, MD, Adjunct Professor, School of Medicine, St. Vincent’s University Hospital, University College Dublin, Dublin, Ireland.

APPENDIX 1.

View this table:
  • View inline
  • View popup
APPENDIX 1.

Feedback from OMERACT participants on the PsAID12.

Footnotes

  • AMO is a Jerome L. Greene Foundation Scholar and is supported in part by a research grant from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases of the US National Institutes of Health under award number P30-AR070254 (Core B), a Rheumatology Research Foundation Scientist Development award, and a Staurulakis Family Discovery award.

  • Accepted for publication November 6, 2018.

REFERENCES

  1. 1.↵
    1. Orbai AM,
    2. de Wit M,
    3. Mease P,
    4. Shea JA,
    5. Gossec L,
    6. Leung YY,
    7. et al.
    International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis 2017;76:673–80.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Orbai AM,
    2. de Wit M,
    3. Mease PJ,
    4. Callis Duffin K,
    5. Elmamoun M,
    6. Tillett W,
    7. et al.
    Updating the Psoriatic Arthritis (PsA) Core Domain Set: a report from the PsA workshop at OMERACT 2016. J Rheumatol 2017;44:1522–8.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Boers M,
    2. Kirwan JR,
    3. Tugwell P,
    4. Beaton D,
    5. Bingham CO III,
    6. Conaghan PG,
    7. et al
    . The OMERACT handbook. [Internet. Accessed November 6, 2018.] Available from: https://omeract.org/resources
  4. 4.↵
    1. Boers M,
    2. Kirwan JR,
    3. Wells G,
    4. Beaton D,
    5. Gossec L,
    6. d’Agostino MA,
    7. et al.
    Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol 2014;67:745–53.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Højgaard P,
    2. Klokker L,
    3. Orbai AM,
    4. Holmsted K,
    5. Bartels EM,
    6. Leung YY,
    7. et al.
    A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: a GRAPPA-OMERACT initiative. Semin Arthritis Rheum 2018;47:654–5.
    OpenUrl
  6. 6.↵
    1. Gossec L,
    2. de Wit M,
    3. Kiltz U,
    4. Braun J,
    5. Kalyoncu U,
    6. Scrivo R,
    7. et al;
    8. EULAR PsAID Taskforce
    . A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 2014;73:1012–9.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    EULAR RAID and PsAID questionnaires. [Internet. Accessed November 6, 2018] Available from: http://pitie-salpetriere.aphp.fr/psaid/raid_psaid_quest_home.php
  8. 8.↵
    1. Tillett W,
    2. Orbai AM,
    3. Ogdie A,
    4. Leung YY,
    5. Strand V,
    6. Gladman DD,
    7. et al;
    8. GRAPPA OMERACT Psoriatic Arthritis working group
    . GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies. Ann Rheum Dis 2018;77:e23.
    OpenUrlFREE Full Text
  9. 9.↵
    1. Holland R,
    2. Højgaard P,
    3. Shea B,
    4. Beaton D,
    5. Tugwell P,
    6. de Wit M,
    7. et al.
    FRI0674 applicability of the PSAID12 questionnaire as a core outcome measure in PsA clinical trials: an evaluation using OMERACT Filter 2.1 instrument selection criteria. Ann Rheum Dis 2018;77:857.
    OpenUrl
  10. 10.↵
    1. Holland R,
    2. Tillett W,
    3. Korendowych E,
    4. Cavill C,
    5. Waldron N,
    6. Brooke M,
    7. et al.
    Validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire and its potential as a single-item outcome measure in clinical practice. Ann Rheum Dis 2018;77:343–7.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Holland R,
    2. Tillett W,
    3. Ogdie A,
    4. Leung YY,
    5. Gladman DD,
    6. Callis Duffin K,
    7. et al.
    Content and face validity and feasibility of 5 candidate instruments for psoriatic arthritis randomized controlled trials: the PsA OMERACT core set workshop at the GRAPPA 2017 Annual Meeting. J Rheumatol 2018;94:17–25.
    OpenUrl
  12. 12.↵
    1. de Wit M,
    2. Kvien TK,
    3. Gossec L
    . Patient participation as an integral part of patient-reported outcomes development ensures the representation of the patient voice: a case study from the field of rheumatology. RMD Open 2015;1:e000129.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Salaffi F,
    2. Di Carlo M,
    3. Carotti M,
    4. Farah S,
    5. Gutierrez M
    . The Psoriatic Arthritis Impact of Disease 12-item questionnaire: equivalence, reliability, validity, and feasibility of the touch-screen administration versus the paper-and-pencil version. Ther Clin Risk Manag 2016;12:631–42.
    OpenUrl
  14. 14.↵
    1. Di Carlo M,
    2. Becciolini A,
    3. Lato V,
    4. Crotti C,
    5. Favalli EG,
    6. Salaffi F
    . The 12-item Psoriatic Arthritis Impact of Disease Questionnaire: construct validity, reliability, and interpretability in a clinical setting. J Rheumatol 2017;44:279–85.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Queiro R,
    2. Cañete JD,
    3. Montilla C,
    4. Abad M,
    5. Montoro M,
    6. Gómez S,
    7. et al.
    Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. Arthritis Res Ther 2017;19:72.
    OpenUrl
  16. 16.↵
    1. Gorlier C,
    2. Orbai A,
    3. Puyraimond-Zemmour D,
    4. Coates LC,
    5. Kiltz U,
    6. Leung YY,
    7. et al.
    Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. Ann Rheum Dis 2018 Nov 15 (E-pub ahead of print).
  17. 17.↵
    1. Gorlier C,
    2. Puyraimond-Zemmour D,
    3. Orbai AM,
    4. Coates LC,
    5. Kiltz U,
    6. Leung YY,
    7. et al.
    Defining cutoffs corresponding to low levels of disease activity in psoriatic arthritis, using the patient-reported psoriatic arthritis impact of disease questionnaire (PsAID12): an analysis of 436 patients [abstract]. Arthritis Rheumatol 2018;70 Suppl 10:965.
    OpenUrl
  18. 18.↵
    1. Orbai AM,
    2. Ogdie A
    . Patient-reported outcomes in psoriatic arthritis. Rheum Dis Clin North Am 2016;42:265–83.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 46, Issue 8
1 Aug 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials
Ana-Maria Orbai, Richard Holland, Ying Ying Leung, William Tillett, Niti Goel, Robin Christensen, Neil McHugh, Laure Gossec, Maarten de Wit, Pil Højgaard, Laura C. Coates, Philip J. Mease, Julie Birt, Lara Fallon, Oliver FitzGerald, Alexis Ogdie, Beverly Shea, Vibeke Strand, Kristina Callis Duffin, Peter Tugwell, Dorcas Beaton, Dafna D. Gladman
The Journal of Rheumatology Aug 2019, 46 (8) 990-995; DOI: 10.3899/jrheum.181077

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials
Ana-Maria Orbai, Richard Holland, Ying Ying Leung, William Tillett, Niti Goel, Robin Christensen, Neil McHugh, Laure Gossec, Maarten de Wit, Pil Højgaard, Laura C. Coates, Philip J. Mease, Julie Birt, Lara Fallon, Oliver FitzGerald, Alexis Ogdie, Beverly Shea, Vibeke Strand, Kristina Callis Duffin, Peter Tugwell, Dorcas Beaton, Dafna D. Gladman
The Journal of Rheumatology Aug 2019, 46 (8) 990-995; DOI: 10.3899/jrheum.181077
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgment
    • APPENDIX 1.
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Keywords

PSORIATIC ARTHRITIS
CORE SET
OUTCOME MEASURES
OMERACT
GRAPPA

Related Articles

Cited By...

More in this TOC Section

  • Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017
  • Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology
Show more Workshops and Special Sessions

Similar Articles

Keywords

  • psoriatic arthritis
  • CORE SET
  • outcome measures
  • OMERACT
  • GRAPPA

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire